カテゴリ： GlobalData, イタリア, 企業調査

Chiesi Farmaceutici SpA：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Chiesi Farmaceutici SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C3316
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：79
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イタリア
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Chiesi Farmaceutici SpA (Chiesi) researches, develops, produces and commercializes novel medicines with focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, ankylosing spondylitis, hypertension, percutaneous coronary intervention, apnoea of prematurity, respiratory distress syndrome (RDS), lipoprotein lipase deficiency (LPLD), limbal stem cell deficiency (LSCD), inflammatory bowel diseases and renal and liver failure – solid organ transplant (SOT). The company operates production sites in Parma, Italy; Blois, France; and Santana De Parnaiba, Brazil; and carries out research and development (R&D) activities at its new R&D center in Parma and at laboratories in Paris, Chippenham (UK), Cary (US), Lidingo (Sweden) and Hillerod (Denmark). Chiesi is headquartered in Parma, Italy.

Chiesi Farmaceutici SpA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 14
Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 15
Atopix Acquires OC459 and CRTH2 Antagonists from Oxagen 17
Venture Financing 19
Atopix Therapeutics Raises Additional Funds through Venture Financing 19
Atopix Therapeutics Raises Funds through Extended Series A Financing 20
Atopix Raises USD5.7 Million in Series A Financing Round 21
Private Equity 22
Charterhouse Capital Partners Acquires Doc Generici For US$424 Million 22
Partnerships 24
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 24
Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 25
Aptuit Enters into Agreement with Chiesi Farmaceutici 26
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 27
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici for Bronchitol in US 28
Chiesi Farmaceutici Enters into Agreement With University College London 29
Pharmathen Enters Into Co-Promotion Agreement With Chiesi For Nebulized Inhaled Corticosteroid 30
Activaero Enters Into Research Agreement With Chiesi Farmaceutici 31
Eddingpharm Forms Joint Venture With Chiesi Farmaceutici 32
Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 33
Licensing Agreements 34
Chiesi Farmaceutici Expands Licensing Agreement with Protalix 34
Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 36
Palladio Biosciences Enters into Agreement with Chiesi USA 37
Aratana Therapeutics Enters into Licensing Agreement with Atopix Therapeutics for CRTH2 38
Cornerstone Therapeutics Enters Into Licensing Agreement With Chiesi Farmaceutici For Bethkis 39
CereSpir Enters Into Licensing Agreement With Chiesi Farmaceutici For CHF 5074 40
Cornerstone Enters Into Licensing Agreement With Digestive Care For Pertzye 41
Asset Transactions 42
Laboratorio Reig Jofre Acquires Right for Heparin Sodium in Spain from Chiesi Espana 42
Neos Therapeutics Acquires Tussionex from Chiesi and Coating Place 43
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 44
Acquisition 45
Chiesi Farmaceutici Acquires Atopix Therapeutics for USD79 Million 45
Chiesi Farmaceutici Completes Acquisition Of Remaining 42% Stake In Cornerstone Therapeutics For US$255 Million 46
Chiesi Farmaceutici Acquires Zymenex from Sunstone Capital 48
Cornerstone Therapeutics Completes Acquisition Of EKR Therapeutics For Up To US$150 Million 49
Cornerstone Therapeutics Acquires Pharma Company, Cardiokine 51
Chiesi Farmaceutici SpA – Key Competitors 52
Chiesi Farmaceutici SpA – Key Employees 53
Chiesi Farmaceutici SpA – Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Recent Developments 57
Product News 57
11/20/2017: Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference 57
11/13/2017: Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union 58
09/07/2017: TRIBUTE study shows superiority of Chiesi’s Trimbow (Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (GB)) over Ultibro (indacaterol/glycopyrronium) in reducing COPD exacerbations 59
06/01/2017: Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Product Facility 60
05/29/2018: Chiesi Group has presented data at two international congresses on the role of its extrafine formulation ICS/LABA/LAMA vs LABA/LAMA in the treatment of COPD patients 61
05/20/2017: Trimbow is the first triple combination in a single inhaler for the treatment of COPD to receive positive opinion from the CHMP in Europe 63
05/09/2017: Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease 64
04/04/2017: For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study 65
02/13/2017: Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium 2017 67
01/29/2018: Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium 2018 68
Product Approvals 69
Jun 12, 2018: Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD) 69
Jan 31, 2018: Protalix BioTherapeutics’ pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration 70
Dec 27, 2017: Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission 71
Oct 09, 2017: Trimbow is accepted for restricted use within NHS Scotland 72
Aug 24, 2017: NICE recommends Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells) for the treatment of moderate to severe limbal stem cell deficiency after eye burns 73
Jul 24, 2017: Chiesi Group receives the European Marketing Authorisation for Trimbow (inhaled corticosteroid / long-acting ß2-agonist / long-acting muscarinic antagonist) 74
Clinical Trials 75
May 25, 2018: Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress 75
Nov 27, 2017: Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference 76
Aug 30, 2017: Inhalation Sciences: PreciseInhale achieves positive results in Chiesi tests 77
Apr 18, 2017: Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79

List of Tables
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Chiesi Farmaceutici SpA, Deals By Therapy Area, 2012 to YTD 2018 9
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 14
Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 15
Atopix Acquires OC459 and CRTH2 Antagonists from Oxagen 17
Atopix Therapeutics Raises Additional Funds through Venture Financing 19
Atopix Therapeutics Raises Funds through Extended Series A Financing 20
Atopix Raises USD5.7 Million in Series A Financing Round 21
Charterhouse Capital Partners Acquires Doc Generici For US$424 Million 22
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 24
Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 25
Aptuit Enters into Agreement with Chiesi Farmaceutici 26
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 27
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici for Bronchitol in US 28
Chiesi Farmaceutici Enters into Agreement With University College London 29
Pharmathen Enters Into Co-Promotion Agreement With Chiesi For Nebulized Inhaled Corticosteroid 30
Activaero Enters Into Research Agreement With Chiesi Farmaceutici 31
Eddingpharm Forms Joint Venture With Chiesi Farmaceutici 32
Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 33
Chiesi Farmaceutici Expands Licensing Agreement with Protalix 34
Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 36
Palladio Biosciences Enters into Agreement with Chiesi USA 37
Aratana Therapeutics Enters into Licensing Agreement with Atopix Therapeutics for CRTH2 38
Cornerstone Therapeutics Enters Into Licensing Agreement With Chiesi Farmaceutici For Bethkis 39
CereSpir Enters Into Licensing Agreement With Chiesi Farmaceutici For CHF 5074 40
Cornerstone Enters Into Licensing Agreement With Digestive Care For Pertzye 41
Laboratorio Reig Jofre Acquires Right for Heparin Sodium in Spain from Chiesi Espana 42
Neos Therapeutics Acquires Tussionex from Chiesi and Coating Place 43
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 44
Chiesi Farmaceutici Acquires Atopix Therapeutics for USD79 Million 45
Chiesi Farmaceutici Completes Acquisition Of Remaining 42% Stake In Cornerstone Therapeutics For US$255 Million 46
Chiesi Farmaceutici Acquires Zymenex from Sunstone Capital 48
Cornerstone Therapeutics Completes Acquisition Of EKR Therapeutics For Up To US$150 Million 49
Cornerstone Therapeutics Acquires Pharma Company, Cardiokine 51
Chiesi Farmaceutici SpA, Key Competitors 52
Chiesi Farmaceutici SpA, Key Employees 53
Chiesi Farmaceutici SpA, Subsidiaries 54

List of Figures
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Chiesi Farmaceutici SpA：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • CMA CGM SA：企業の戦略・SWOT・財務情報
    CMA CGM SA - Strategy, SWOT and Corporate Finance Report Summary CMA CGM SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Trubnaya Metallurgicheskaya Kompaniya：企業の戦略・SWOT・財務情報
    Trubnaya Metallurgicheskaya Kompaniya - Strategy, SWOT and Corporate Finance Report Summary Trubnaya Metallurgicheskaya Kompaniya - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Callitas Therapeutics Inc (LILY)：製薬・医療：M&Aディール及び事業提携情報
    Summary Callitas Therapeutics Inc (Callitas Therapeutics), formerly M Pharmaceutical Inc, is a drug discovery and development company that offers ground-breaking drug treatments and biomedical technologies. The company’s products include weight management products, infertility products and women’s h …
  • Regeneron Pharmaceuticals Inc (REGN)-製薬・医療分野：企業M&A・提携分析
    Summary Regeneron Pharmaceuticals Inc (Regeneron) is a biopharmaceutical company which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company provides products for treating eye diseases, high low-density lipoprotein (LDL) choleste …
  • Mitobridge Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Mitobridge Inc (Mitobridge), formerly Mitokyne Inc, a subsidiary of Astellas Pharma Inc is a drug development company that discovers and develops small molecule therapeutics that recovers mitochondrial functions. The company develops therapies for rare diseases and expands into more common d …
  • Murata Manufacturing Co Ltd (6981)：医療機器：M&Aディール及び事業提携情報
    Summary Murata Manufacturing Co., Ltd. (Murata) is an electronic component manufacturing company that designs, manufactures, and supplies a range of advanced electronic materials, components, and multi-functional, high-density modules. Its product portfolio includes capacitors, inductors, resistors, …
  • Ardelyx Inc (ARDX)：企業の財務・戦略的SWOT分析
    Summary Ardelyx Inc (Ardelyx) is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company provides product portfolio such as tenapanor, RDX227675, RDX98940 and RDX013, among others. Its products are used for hyperphosphatemia in …
  • Cullen Resources Ltd：企業の財務・戦略的SWOT分析
    Summary Cullen Resources Ltd (Cullen) is a mining company that offers mineral exploration solutions. The company carries out the business of acquisition, exploration, and development of copper, iron, gold, and nickel properties. Its projects include West Pilbara Iron Ore project, Wyloo project, West …
  • Sv. Sv. Konstantin I Elena Holding Ad：企業の戦略・SWOT・財務分析
    Sv. Sv. Konstantin I Elena Holding Ad - Strategy, SWOT and Corporate Finance Report Summary Sv. Sv. Konstantin I Elena Holding Ad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • ET Solar Group Corporation：企業の戦略的SWOT分析
    ET Solar Group Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Sandoz Inc：企業のM&A・事業提携・投資動向
    Sandoz Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sandoz Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Endress+Hauser AG：企業の戦略的SWOT分析
    Endress+Hauser AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • UniQuest Pty Ltd-製薬・医療分野：企業M&A・提携分析
    Summary UniQuest Pty Ltd (UniQuest), a subsidiary of The University of Queensland is a commercialization company that offers consultancy services. The company commercializes intellectual property and research outcomes of University of Queensland. It offers services such as eShop, witness, contract r …
  • Bonnier AB：企業の戦略的SWOT分析
    Bonnier AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Leadiant Biosciences Inc-製薬・医療分野：企業M&A・提携分析
    Summary Leadiant Biosciences Inc (Leadiant Biosciences) a subsidiary of Sigma-Tau SpA is a pharmaceutical company that discovers and develops novel medicines. The company offers products such as Cystaran, Carnitor, Matulane, Adagen, Abelcet, DepoCyt, ProXeed Plus, VSL and Colief products. It offers …
  • Peabody Energy Corp：企業の戦略・SWOT・財務分析
    Peabody Energy Corp - Strategy, SWOT and Corporate Finance Report Summary Peabody Energy Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Sharp Corporation (6753)：電力：M&Aディール及び事業提携情報
    Summary Sharp Corp (Sharp) designs, develops, and markets digital information equipment, health and environmental equipment, energy and business solutions. The company’s major products are refrigerators, microwave ovens, air conditioners, washing machines, electric fans, beauty appliances, LED light …
  • Talktalk Telecom Group PLC (TALK)：企業の戦略的SWOT分析
    Talktalk Telecom Group PLC (TALK) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Finbar Group Ltd (FRI)：企業の財務・戦略的SWOT分析
    Finbar Group Ltd (FRI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Alphatec Holdings Inc (ATEC)：医療機器：M&Aディール及び事業提携情報
    Summary Alphatec Holdings Inc (Alphatec) is a medical technology company that focuses on the design, development and marketing of spinal fusion technology products and solutions for the treatment of spine disorders. The company’s major products include anterior cervical plate system, posterior cervi …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆